

DISCLOSURES OF RELATIONSHIPS

In order for the College to most effectively further its mission and to otherwise maintain its excellent reputation in the medical community and with the public, it is important that confidence in the College's integrity be maintained. The cornerstone of the ACR's Disclosure Policy is disclosure of actual and potential conflicts so that they can be evaluated by the College in order to avoid undue influence of potential conflicts.

The purpose of the ACR's Disclosure Policy is identification of relationships which may pose actual or potential conflicts. These actual or potential conflicts can then be evaluated by the College so that adjustments can be made that will avoid any undue influence.

This policy is based on the principle that, in many cases, full disclosure of the actual or potentially conflicting relationship will of itself suffice to protect the integrity of the College and its interests.

| Participants | Role | Primary employer | Sources of personal income to include speakers bureau, honoraria, royalties, expert witness fees, advisory boards, or any other sources of income (excludes salary from primary employer) | Research Grants/Contracts | Investments to include medical industry and non-medical industry | Organizational Benefit | Activities with other organizations | Family or other relations |
|---|--|--|---|---|--|------------------------|---|---------------------------|
| Liana Fraenkel | Committee on Quality of Care, Chair | Yale University; VA Connecticut | | RRF; VA; NIAMS; PCORI | | | | |
| Daniel Aletaha <i>Disclosure Forthcoming</i> | Committee on Quality of Care | Medical University of Vienna | | | | | | |
| Timothy Beukelman | Committee on Quality of Care / Practice Guidelines Subcommittee, Chair | University of Alabama at Birmingham | Genentech/Roche; Mckesson Health Solutions; UCB; Vindico; Spire Learning; Novarits | NIH/NIAMS; PCORI; AHRQ; Childhood Arthritis and Rheumatology Research Alliance | | | Childhood Arthritis and Rheumatology Research Alliance; Journal of Rheumatology | |
| Matthew Bunyard | Committee on Quality of Care | Cleveland Clinic Foundation | | | | | | Spouse |
| Laura Cappelli | Committee on Quality of Care | John Hopkins University | | | | | | |
| Leslie Harrold | Committee on Quality of Care | UMass Medical School | Pfizer | AHRQ; Corrona; Astra Zeneca | | | | |
| Nadine T. James | Committee on Quality of Care | Forrest General Hospital; Simmons College | | | | | | |
| Charles King | Committee on Quality of Care | North Mississippi Health Services | Pfizer; Independent Grants for Learning & Change; NACE | Eli Lilly; Janssen Research & Development, LLC; Boehringer Ingelheim; EMD Serono, Inc., Pfizer; Sanofi; Novartis; Sanofi; UCB; Roche; Pfizer; Consortium of Rheumatology Researchers of North America, Inc. | Medimergent | | | |
| Alex Limanni | Committee on Quality of Care | Self-employed | Baylor University Medical Center | Novartis; Janssen; Abbvie; Human Genome Sciences/Glaxo; Amgen | | | Baylor University Medical Center | |
| L. Nandini Moorthy | Committee on Quality of Care | Rutgers Robert Wood Johnson Medical School | ACR | | | | NJAAP; AAP Editor | Spouse |
| Tuhina Neogi | Committee on Quality of Care | Boston University School of Medicine | | NIH; AF | | | OARSI | |

The 2010 ACR / EULAR Classification Criteria for RA - Methodological Report Phase 2

| | | | | | | | | |
|------------------------|----------------------------------|---|--|----------------------------------|-----------------------|--|----------------------------------|--|
| Lisa Suter | Committee on Quality of Care | Yale University; West Haven VAMC | | | | | AAOS | |
| Beth H. Resman-Targoff | Committee on Quality of Care | University of Oklahoma College of Pharmacy | American Pharmacists Association | | | | Annals of Pharmacotherapy | Spouse |
| Patience White | Committee on Quality of Care | Self-employed | NIH | BMCH | | | | Spouse |
| Chad Deal | Practice Guidelines Subcommittee | Cleveland Clinic Foundation | Amgen; Lilly | | | | | |
| Atul Deodhar | Practice Guidelines Subcommittee | Oregon Health & Science University | Abbvie; Amgen; Pfizer; Novartis; Janssen; UCB; Boehringer Ingelheim | | | | SPARTAN-GRAPPA Symposium | |
| John FitzGerald | Practice Guidelines Subcommittee | UCLA | | RAND | | | | |
| Gerald Levy | Practice Guidelines Subcommittee | SCPMG | | Kaiser | MannKind | | | |
| Pamela Weiss | Practice Guidelines Subcommittee | Children's Hospital of Philadelphia | Lilly | NIH; J&J | | | | |
| Catherine Christen | Practice Guidelines Subcommittee | University of Michigan Health System | | | | | Michigan Ovarian Cancer Alliance | |
| Elizabeth Salt | Practice Guidelines Subcommittee | University of Kentucky | Pfizer | NIH; ACR | | | | |
| Abbey Abelson | ACR Board of Directors | Cleveland Clinic Foundation | American Board of Internal Medicine | | | | | |
| Bruce Cronstein | ACR Board of Directors | NYU School of Medicine | NIH; AstraZeneca; Gilead; Arthritis Foundation; Bristol-Myers Squibb; Pfizer | | | | Arthritis Foundation | Spouse- Employed by Hospital for Special Surgery |
| Deborah Dyett Desir | ACR Board of Directors | Arthritis & Osteoporosis Center | | | Horizon Pharma; Vivus | | | |
| David Daikh | ACR Board of Directors | University of California San Francisco; San Francisco VA Medical Center | | NIAMS | | | | |
| Joseph Flood | ACR Board of Directors | Musculoskeletal Medical Specialists, Inc. | Pfizer; Novartis; Amgen; Forest; Takeda | Rheumatology Research Foundation | | | Ohio State; Arthritis Foundation | |

The 2010 ACR / EULAR Classification Criteria for RA - Methodological Report Phase 2

| | | | | | | | | |
|----------------------|---------------------------------------|---|--|--|-----------------------------|----------------------------|---|--|
| Richard Furie | ACR Board of Directors | North Shore University Hospital; NYU School of Medicine | Abbvie; Astellas; BiogenIdec; BMS; Celgene; Chugai; Eli Lilly; Exagen; Genetech/Roche; GlaxoSmithKline; Medimmune; Lycera; Merck; Onyx; Questcor Pharmaceuticals; Rigel; UCB | Amgen; Anthera; BiogenIdec; BMS; Boehringer-Ingelheim; Celgene; Dynavax; Eli Lilly; Exagen; Genetech/Roche; GlaxoSmithKline; Medimmune; Novartis; Questcor Pharmaceuticals; Rigel; UCB; Pfizer; Takeda | Pfizer | | Lupus Foundation of America; Lupus Alliance of America; SLE Foundation; Alliance for Lupus Research | |
| Emily Isaacs | ACR Board of Directors | Medical Clinic of North Texas | AbbVie, Amgen, Pfizer, Celgene, Janssen, Crescendo | | | | | |
| Joanne M. Jordan | ACR Board of Directors | University of North Carolina | PolyActiva; Samumed; Osteoarthritis & Cartilage | NIAMS/NIH; CDC | | US Bone & Joint Initiative | Osteoarthritis Research Society International; US Bone & Joint Initiative | Spouse; child |
| David Karp | ACR Board of Directors | UT Southwestern Medical Center | National Institutes of Health | National Institutes of Health, Univesrity of Pittsburgh, Bristol Myers Squibb, Glaxo Smith Kline, Human Genome Scineces, Inc., Genentech, Inc., Merck, Inc.; - UT Southwestern Medical Center | | | Lupus Foundation of America | |
| Sharad Lakhanpal | ACR Board of Directors | Rheumatology Associates | BMS, Meetings and Events Intl, Interpublic Group, Healthlogix, APOD, Lpmhealthcare | | | | | |
| Timothy Laing | ACR Board of Directors | University of Michigan Medical Center | Celgene, Curis | Acadia Pharmaceuticals, Compugen Ltd, Lpath Inc | | | | |
| Paula Marchetta | ACR Board of Directors | Concorde Medical Group, PLLC; University Physicians Network | | | | | | |
| Eric Matteson | ACR Board of Directors | Mayo Clinic College of Medicine | Vasculitis Foundation | NIH, Ardea, Pfizer, Novartis, Sanofi, Centocor-Jansen, Celgene, Amgen, Roche, Genentech, Mesoblast | | | | |
| Zsuzsanna H. McMahan | ACR Board of Directors | Johns Hopkins Medicine | ACR, Johns Hopkins University CME Course | Rheumatology Research Foundation, Maryland Technology Development Corporation, Jerome L. Greene Discovery Award | | | | Father - Consultant for Pharma Companies |
| Rodolfo Molina | ACR Board of Directors | Arthritis Associates PA | Texas Medical Board | | | | | |
| Kamala Nola | ACR Board of Directors | Lipscomb University | | | | | American Board of Pediatrics, Pediatric Nephrology | |
| Marilynn Punaro | ACR Board of Directors | University of Texas Southwestern | | | | | | |
| Kenneth Saag | ACR Board of Directors | University of Alabama at Birmingham | Abbott, Amgen, Ardea, Bayer, BMS, Crealta, Lilly, Merck | NIAMS, AHRQ | | | National Osteoporosis Foundation, American Gout Society, Current Opinions in Rheumatology, Neurological, Aging, and Musculoskeletal Epidemiology, Medscape Rheumatology | |
| E. William St.Clair | ACR Board of Directors, ACR President | Duke University Medical Center | Up-To-Date | NIAID, Biogen Idec; Rauch Family Fund | Bristol Myers Squibb, Merck | | | |
| Joan von Feldt | ACR Board of Directors | University of Pennsylvania Philadelphia VA Medical Center | Novartis | UCB | | | Wolters Klueter | |